Skip to main content
SpringerLink
Log in

PD-1-Blocker in der Zweitlinie beim Melanom

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Kommt es beim fortgeschrittenen malignen Melanom trotz Ipilimumab und BRAF-Inhibitoren zum Progress — lohnt sich dann in der Zweit- oder Drittlinie eine PD-1-Checkpointinhibition mehr als eine Chemotherapie?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Weber JS et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–84

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Kathrin von Kieseritzky

Authors
  1. Kathrin von Kieseritzky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

von Kieseritzky, K. PD-1-Blocker in der Zweitlinie beim Melanom. hautnah dermatologie 31, 23 (2015). https://doi.org/10.1007/s15012-015-1887-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1887-8

Search

Navigation